Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
R&D Strategies in securing funding for rare disease research An outline of emerging financing strategies for rare disease research in challenging times.
R&D JP Morgan 2023 - Astrocyte Pharmaceuticals pharmaphorum spoke with Astrocyte's Kevin Sheth, William Korinek, and James D. Lechleiter
R&D Advanced manufacturing to pave way for pharma industry The time for transition to sustainable strategies is now.
R&D A look back at RNA Therapeutics – day one The 14th Annual RNA Therapeutics Conference took place in Kensington, London this year.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
